Similar Results Found From Primary Kidney Cells & Transplant Recipients

Using primary human cells in your in vitro models can greatly enhance the biological relevance of your research, resulting in real human insights.

Cell Systems Primary Human Glomerular Endothelial Cells (Cat#. ACBRI 128) were used in a human in vitro model by the University Health Center of Quebec to better understand chronic antibody-mediated rejection (ABMR) in kidney transplant recipients.

In this study, researchers compared the effects of the drug tacrolimus on the secretion level of vWF in both the in vitro glomerular endothelium model as well as in patients. vWF is a thrombotic glycoprotein whose elevated level can be associated with ABMR.

Across multiple experiments in the study, the results gathered from the primary glomerular cell model show similar patterns to what was observed in actual patients. Data from both the in vitro and in vivo models suggest that tacrolimus lowers the secretion of vWF and can help prevent alloantibody-mediated graft damage.

In vitro experiments are simpler and more affordable than experiments with human subjects, but they do not always provide relevant data due to the physiological differences. However, because primary human cells are directly derived from human tissues, they can notably increase the relevance of research models, thereby saving time and money down the road.

Unlike most providers, Cell Systems isolates primary human cells without the use of antibodies to ensure the greatest biological relevance of your research.

For similar peer-reviewed publications citing our Primary Human Glomerular Endothelial Cells (Cat#. ACBRI 128), please visit our website or contact us at


Study: Tacrolimus prevents von Willebrand factor secretion by allostimulated human glomerular endothelium by Béland S, Désy O, Ung RV, et al.

Older Post Newer Post